Beta Drugs Ltd

- No significant CAPEX or major fundraising is currently planned for the next couple of years. - Recent CAPEX was minimal (around 70-80 lakhs in FY21), mainly for small capacity additions and regulatory expenses. - Future CAPEX related to regulatory compliance is expected to be small (2-3 crores). - For new capacities like injectable lines, planned CAPEX is estimated at 40-45 crores, with a timeline of around 1 to 14 months after capacity reaches 80%-90% utilization. - No explicit mention of raising debt or equity funding at present or in the near term. - Company is conserving cash primarily for international market expansion and regulatory approvals rather than dividend payouts. - No concrete plans disclosed regarding any new fundraising through debt or equity in the immediate future.

- Recent CAPEX in FY21 was modest, around Rs. 70-80 lakhs, mostly small reactor additions. - No significant CAPEX required immediately; current Indian plant capacity supports turnover up to Rs. 250 crores without expansion. - Small planned expenditure of Rs. 2-3 crores for regulatory compliance and filings towards regulated markets. - Future major CAPEX planned for expanding injectable manufacturing lines, with land already acquired. - Estimated cost for injectable line expansion is Rs. 40-45 crores, with a timeline of about 12 to 14 months after capacity utilization reaches 80-90%. - Long-term plan to enter biosimilars requires substantial CAPEX (~Rs. 300 crores), but this will be considered after strengthening domestic and international presence in small molecule TKIs. - Uzbekistan plant recently operational; consolidation and ramp-up expected, but cash repatriation and capex issues appear managed.

- Beta Drugs expects a Compound Annual Growth Rate (CAGR) of 30%-35% in topline/sales over the next 4-5 years (Page 20, 22). - Targets for FY 2021-22 set at ₹153 crore with EBITDA margins of 23%-24% (Page 20). - Plans to reach capacity utilization of 80%-90%, after which further injectable manufacturing lines will be added, costing ₹40-45 crore with a 12-14 month timeline (Page 22). - Own domestic market sales expected to grow to ₹75-80 crore in 4-5 years (Page 12). - Export sales projected to increase to ₹60-70 crore in the next 4-5 years (Page 12). - API business to scale up to ₹40-50 crore or more within 4-5 years (Page 12). - Uzbekistan plant contributing ₹40-50 crore in oral sales with good EBITDA margins (Page 9). - Growth will be multi-segment, including domestic formulations, exports, APIs, and contract manufacturing (Page 11, 12).

- Beta Drugs targets 30%-35% CAGR growth over the next 4-5 years, depending on pandemic conditions (Page 20). - EBITDA margin expected to increase by 1% to 1.5% annually with operating leverage (Page 20). - EBITDA margins for FY 2021-22 targeted at 23%-24% at a turnover of Rs. 153 crores (Page 20, 9). - Operating leverage expected to improve margins beyond 24% as revenue approaches Rs. 250 crores capacity (Page 9). - Own brand business gives EBITDA margin ~36%; exports ~26%; CMO business ~16%; EPI ~18.5% (Page 21). - EPS in FY21 was Rs. 12; no current plans for dividends as cash is conserved for international expansion (Page 10). - R&D investment expected around 2%-3% of turnover to support sustained growth (Page 11).

The transcript does not explicitly mention the current or expected order book or pending orders for Beta Drugs Limited. However, based on the discussion: - The company anticipates 30%-35% CAGR over the next 2-3 years, indicating a strong order inflow. - They have recently added major clients like Reliance Life Sciences and are in talks with Fresenius Kabi and Lupin for potential audits and orders. - They have ongoing manufacturing contracts for products in oncology with Reliance and others. - Growth is expected from multiple divisions: domestic formulations, international exports, and APIs. - The Uzbekistan plant is operational, contributing to revenues and expanding market presence, particularly in CIS countries. - Capacity utilization is expected to reach 80%-90% next year, which suggests robust demand and ongoing orders. No specific order book figure or exact pending orders data is provided.